1. Cysticlean® a highly pac standardized content in the prevention of recurrent urinary tract infections: an observational, prospective cohort study
- Author
-
Vicente Ruiz Vidal, Ana María Oltra Benavent, Eva Escudero Fontano, Emilio López Alcina, Cristina Domenech Perez, Francisco Sánchez Ballester, Marco Andrés Sobrón Bustamante, and Ana Montoliu García
- Subjects
Adult ,QoL ,medicine.medical_specialty ,Adolescent ,medicine.drug_class ,Urinary system ,Urology ,Antibiotics ,Single Center ,Cohort Studies ,Young Adult ,Quality of life ,Internal medicine ,Cystitis ,Secondary Prevention ,medicine ,Humans ,Cranberry ,Postcoital ,Proanthocyanidins ,Prospective Studies ,Young adult ,Prospective cohort study ,Gynecology ,Cysticlean® ,business.industry ,Coitus ,Bacterial Infections ,General Medicine ,Middle Aged ,Urinary tract infections ,United States ,Anti-Bacterial Agents ,Treatment Outcome ,Reproductive Medicine ,Spain ,Dietary Supplements ,Quality of Life ,Female ,Observational study ,business ,Research Article ,Cohort study - Abstract
Background The present study was aimed at determining the prophylactic efficacy of American cranberry (AC) extract (Cysticlean®) in women with recurrent symptomatic postcoital urinary tract infections (PCUTI), non-consumer of AC extract in the past 3 months before inclusion, and to determine changes in their quality of life (QoL). Methods This was a single center, observational, prospective study in a total of 20 women (mean age 35.2 years; 50.0% were married). Patients were followed up for 3 and 6 months during treatment. Results The number of PCUTIs in the previous 3 months prior to start the treatment with Cysticlean® was 2.8±1.3 and it was reduced to 0.2±0.5 at Month 6 (P
- Full Text
- View/download PDF